METHOD OF TREATING AFFECTIVE DISORDERS AND PERSONALITY DISORDERS
As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.
1 . A method for improving cognitive function and/or life satisfaction in a subject, the method comprising administering to the subject a combination therapy comprising a first agent selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil and a second agent that is telmisartan or candesartan.
2 . The method of claim 1 , wherein the second agent is telmisartan.
3 . The method of claim 1 , wherein the effective amount of the first agent is from about 120 mg to about 720 mg and the effective amount of the second agent is from about 45 mg to about 180 mg.
4 . The method of claim 1 , wherein the combination therapy comprises 120-360 mg of verapamil and 40 to 180 of telmisartan.
5 . The therapeutic combination of claim 1 , wherein the therapeutic combination further comprises magnesium oxide.
6 . The method of claim 1 , wherein the therapeutic combination is administered once or twice daily.
7 . The method of claim 1 , wherein the amount of the first agent is from about 1 to about 4 times the amount of the second agent.
8 . A method of treating a neurodevelopmental disorder in a subject, the method comprising administering to the subject a combination therapy comprising a first agent selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil; and a second agent that is telmisartan or candesartan, wherein the neurodevelopmental disorder is selected from the group consisting of autism spectrum disorder, attention deficit hyperactive disorder (ADHD) and learning disorder.
9 . The method of claim 8 , wherein the first agent is verapamil and the second agent is telmisartan.
10 . The method of claim 8 , wherein the effective amount of the first agent is from about 120 mg to about 720 mg and the effective amount of the second agent is from about 45 mg to about 180 mg.
11 . The method of claim 8 , wherein the combination therapy comprises 120-360 mg of verapamil and 40 to 180 of telmisartan.
12 . The method of claim 8 , wherein the therapeutic combination is administered once or twice daily.
13 . A pharmaceutical composition comprising effective amounts of a first and second agent and a pharmaceutically acceptable excipient, wherein the first agent is selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil and the second agent is selected from one or more of telmisartan and candesartan.
14 . A kit comprising a therapeutic combination comprising a therapeutic combination comprising a first and second agent, wherein the first agent is selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil and the second agent is selected from one or more of telmisartan and candesartan, and instructions for the use of the combination for the treatment of a brain and/or behavioral health disorder or a symptom thereof.
15 . A method of treating addition and/or substance abuse in a subject, the method comprising administering to the subject a combination therapy comprising a first agent selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil; and a second agent that is telmisartan or candesartan.
16 . A method of treating a migraine disorder and/or somatoform disorder in a subject, the method comprising administering to the subject a combination therapy comprising a first agent selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil; and a second agent that is telmisartan or candesartan.
17 . A method of treating a psychotic disorder in a subject, the method comprising administering to the subject a combination therapy comprising a first agent selected from the group consisting of anipamil, devapamil, falipamil, gallopamil, tiapamil, and verapamil; and a second agent that is telmisartan or candesartan, thereby effecting an improvement in cognitive function and/or life satisfaction in the subject.